APN1125

DRUG2 trials

Sponsors

CoMentis

Conditions

Schizophrenia

Phase 1

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

CompletedNCT02331433

CoMentisSchizophrenia

Start: 2014-12-31End: 2015-12-31Updated: 2016-04-08

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

SuspendedNCT02724917

CoMentisSchizophrenia

Start: 2016-04-30End: 2016-12-31Target: 30Updated: 2016-07-13